BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Mark W. Lingen
Associate Professor
eRA COMMONS USER NAME
MLINGEN
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DePauw University, Greencastle, IN
Northwestern University, Chicago, IL
Northwestern University, Evanston, IL
DEGREE
(if applicable)
YEAR(s)
B.A.
D.D.S.
Ph.D.
1982-1986
1986-1990
1990-1996
FIELD OF STUDY
Zoology
Dentistry
Pathology
A. Personal Statement
For the past 15 years, my laboratory has focused predominantly on several basic and translational aspects of
tumor angiogenesis, with a focus on tumors of epithelial origin. My laboratory has been heavily involved in large
scale genomic analyses to understand how treatment of head and neck tumors influences the transcriptome. We
have discovered unique pathways that may explain positive or negative responses of tumors to anti-angiogenic
agents. More specifically, we are pursuing the hypothesis that inhibitors of angiogenesis may be useful in a
chemoprevention setting, using head and neck squamous cell carcinoma (HNSCC) as a model. In addition, we are
pursuing molecularly-based diagnostic protocols for HNSCC. Current diagnostic techniques for premalignant
disease, based upon histologic recognition of nuclear and cellular atypia, are relatively poor predictors of ultimate
clinical outcome. Since morphological or cytological changes may occur late in the process of transformation,
histologically benign-appearing lesions may have malignant potential. Therefore, methods for detecting
molecularly pre-malignant lesions at an earlier stage are required. The long-term goal of this work is to define a
profile of molecular markers of premalignancy for HNSCC. Overall, our work addresses innovative questions that
will have significant implications for the fields of angiogenesis, epithelial cell biology, and cancer.
B. Positions and Honors
Positions and Employment
1990-1994
Residency, Oral and Maxillofacial Pathology, Northwestern University Dental School,
Chicago, IL
1994-1995
Fellowship, Oral and Maxillofacial Pathology, Northwestern University Dental School,
Chicago, IL
1996-1998
Assistant Professor, Department of Pathology, Northwestern University Medical School,
Chicago, IL
1998-2001
Assistant Professor, Department of Pathology, Loyola University Medical Center, Maywood,
IL
2001-2002
Associate Professor, Department of Pathology, Loyola University Medical Center, Maywood, IL
2002-Present
Associate Professor, Department of Pathology, The University of Chicago, Chicago, IL
Other Experience and Professional Memberships
2004Member, External Advisory Committee, UC Irvine, Phase III Head and Neck Chemoprevention
Clinical Trial
2006Member, Council on Scientific Affairs, The American Dental Association (ADA)
2006
Chair, NIH/NCI, Special Emphasis Panel, Oral Complications of Cancer Therapies
2006
NIH/NCI, Basic Mechanisms of Cancer Therapeutics (BMCT), Study Section ad hoc
reviewer
2007Member, ADA Expert Panel Working Group on Oral Cancer Screening
2008Associate Editor, Laboratory Investigation
Principal Investigator/Program Director (Last, First, Middle):
2008
20082008
2008
2009
2012
Vice-Chair, NIH/NIDCR Special Emphasis Panel, Translational Application of Gene
Silencing Strategies to Oral and Craniofacial Disorders
Member, Scientific Advisory Board, The Chicago Innovative Center in Wound Healing
Research (NIH P20 Award)
Member, External Advisory Committee, Paffenbarger Research Center
Member, ADA Expert Panel Working Group on Salivary Diagnostics
NIH/NCI, Tumor Microenvironment (TME) Study Section, ad hoc reviewer
Chair, NIH/NIDCR Special Emphasis Panel/Scientific Review Group ZDE1 JH 30
Member, External Advisory Board, MD Anderson Head and Neck SPORE
Honors
1991-1996
2000
2002
2006
2012
NIH Individual Dentist Scientist Fellowship
Fellow, American College of Dentists
Northwestern University Alumni Merit Award
Fellow, International College of Dentists
Fellow, Royal College of Pathologists (FRCPath)
2008-
C. Selected Peer-reviewed Publications (Selected from over 90 publications)
1. Lingen MW, DiPietro, LA, Solt, DB, Bouck, NP, and Polverini, PJ. The angiogenic phenotype in hamster
buccal pouch keratinocytes is dependent on TGFβ-1 and is unaffected by Ras activation. Carcinogenesis,
18:329-338, 1997.
2. Lingen MW, Polverini PJ, and Bouck NP. Retinoic acid and interferon-α act synergistically to inhibit oral
squamous cell carcinoma induced angiogenesis. Cancer Research, 58:5551-5558, 1998.
3. Kini A, Peterson L, Tallman MS, Lingen MW. All-trans retinoic acid inhibits vascular endothelial growth
factor (VEGF)-mediated angiogenesis in acute promyelocytic leukemia. Blood, 97:3919-3924, 2001.
4. Cline EI, Bicciato S, DiBello C, Lingen MW. Prediction of in vivo synergistic anti-angiogenic activity by
gene expression profiling. Cancer Research, 62:7143-7148, 2002.
5. Hasina R, Hulett K, Bicciato S, Petruzzelli G, Lingen MW. Identification of PAI-2 as a predictor of
progression in oral squamous cell carcinoma. Cancer Research, 63:555-559, 2003.
6. Cohen EEW, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC,
Dahiya S, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW.The Response Of Squamous Cell
Carcinomas Of The Head & Neck To Tyrosine Kinase Inhibitors Of The Epidermal Growth Factor Receptor
Is Not Associated With Mutations In The Receptor. Clinical Cancer Research, 11: 8105-8108, 2005.
7. Hasina R, Fekete MJ, Martin L, Qi X-M, Brigaudeau C, Pramanik R, Edith I. Cline, Coignet L, Lingen MW.
NOL7 is a Nucleolar Candidate Tumor Supressor Gene in Cervical Cancer that Modulates the Angiogenic
Phenotype. Oncogene, 25:588-598, 2006.
8. Hasina R, Whipple M, Kuo WP, Martin L, Ohno-Machado L, Lingen, MW. Angiogenic Heterogeneity in
Head and Neck Squamous Cell Carcinoma: Biologic and Therapeutic Implications. Laboratory Investigation,
88:342-353, 2008. PMCID: PMC2614382
9. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R,
Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell
carcinoma, 69:3021-3031, 2009. PMCID: PMC2871252
10. Hasina R, Martin LE, Jones C, Jalil A, Lingen MW. ABT-510 is an Effective Chemopreventive Agent in
the 4NQO Mouse Model of Oral Carcinogenesis. Cancer Prevention Research, 2:385-393, 2009. PMCID:
PMC2702843
11. Doebele DC, Schulze-Hoepfner F, Hong J, Chlenski A, Zeitlin B, Goel K, Gomes S, Liu Y, Abe M, Nor
JE, Lingen MW, Rosner MR. A Novel Interplay between Epac/Rap1 and MEK5/ERK5 regulates
thrombospondin production to control angiogenesis. Blood, 114:4592-4600, 2009. PMCID: PMC2777131
12. Mankame TP, Zhou G, Lingen MW. Identification and characterization of the human NOL7 gene
promoter. Gene 456:36-44 2010. PMC Journal in Process
13. Zhou G, Jones C, Lingen MW. Identification and Functional Characterization of the Nuclear and
Nucleolar Localization Signals in NOL7. BMC Cell Biology, 11:74-93, 2010. PMCID: PMC2957388
Principal Investigator/Program Director (Last, First, Middle):
14. Zhou G, Hasina R, Wroblewski K, Mankame TP, Doci CL, Lingen MW. Dual Inhibition of VEGFR and
EGFR is an Effective Chemopreventive Strategy in the Mouse 4NQO Model of Oral Carcinogenesis. Cancer
Prevention Research, 3:1493-1502, 2010. PMC Journal in Process
15. Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R,
Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression
in cervical cancer. International Journal of Gynecological Pathology, 31:15-24, 2011. PMCID: PMC3237951
C. RESEARCH SUPPORT
Ongoing
RC2 DE020779-01
NIH (Lingen)
9/30/09-9/29/12
Efficacy of Oral Cancer Screening Adjuncts
The goal of this planning grant is to design a multi-centered randomized controlled trial to compare and
estimate the diagnostic accuracy of 3 oral cancer screening regimens, develop a tactical plan for the safe,
rapid and rigorous execution of the proposed trial, and to develop a manual of procedures for conducting the
proposed trial.
Lederer Foundation. (Lingen)
4/1/11-3/31/13
c-Met Inhibitors for the Prevention of Esophageal Squamous Cell Carcinoma.
The major goal of this grant is to test the hypothesis that c-Met inhibitors have activity as chemopreventive
agents in a mouse pre-clinical model of premalignancies of the upper aerodigestive tract.
2P30 CA014599-33 (Le Beau)
07/22/08-3/31/13
NIH/NCI
Cancer Center Support Grant
The overall goal of the University of Chicago Cancer Research Center is to improve the prevention, detection,
and treatment of cancer through our basic, clinical, translational, and population research activities. The
mission of the HTRC is to provide cancer investigators with a centralized infrastructure to optimize the
efficiency and costs related to research involving human bio-specimens.
Role: Scientific Director of the Bio-specimen Bank
Completed
Illinois Department of Public Health
7/1/08 – 6/30/09
.
Characterization of the Nucleolar Tumor Suppressor Gene NOL7 in Cervical Cancer
The major goal of this pilot grant was to determine if NOL7 was potentially inactivated via either somatic
mutations within the gene and/or by methylation of the promoter region.
Role: Principal Investigator
R01 DE015830
NIH/NIDCR (Lingen)
Molecular Profiling of Premalignant Oral Lesions
7/18/05-6/30/09
The goal of this proposal is to identify a panel of Biomarkers that identify molecularly premalignant lesions.
5 R01 DE012322-12
NIH (Lingen)
8/1/05-5/31/2010
Oral Cancer, Chemoprevention and Anti-Angiogenesis
The major goal of this proposal is to develop novel, nontoxic chemopreventive strategies for HNSCC that are
based upon the inhibition of angiogenesis.
Role: Principal Investigator